Literature DB >> 9443939

Mechanism of YC-1-induced activation of soluble guanylyl cyclase.

A Friebe1, D Koesling.   

Abstract

The signaling molecule nitric oxide (NO) mediates many of its effects by the stimulation of soluble guanylyl cyclase (sGC). The activation process is initiated by high-affinity binding of NO to the enzyme's prosthetic heme group. Despite its poor sGC-activating properties, carbon monoxide (CO) has also been suggested as a physiological activator of sGC. Recently, we have shown that the substance YC-1, a benzyl indazole derivative, stimulates sGC by 10-fold (independently of NO) potentiates the stimulatory effect of NO, and turns CO into a potent activator of sGC. In the present study, we show that activation of sGC by protoporphyrin IX, a ligand-independent activator, was potentiated by YC-1, yet a shift of the concentration-response curve as seen with NO and CO was not observed. YC-1 slowed down the dissociation rates for NO and CO from the activated enzyme as monitored by cGMP accumulation after addition of the NO and CO scavenger oxyhemoglobin. A direct interaction of YC-1 with the heme group can be ruled out because YC-1 did not change the Soret absorption of basal or stimulated sGC and, in addition, still bound to the heme-depleted enzyme. Together, our results indicate that YC-1 increases the maximal catalytic rate and sensitizes the enzyme toward its gaseous activators by binding to an allosteric site on sGC molecules, thereby reducing the ligand dissociation rate from the heme group.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443939     DOI: 10.1124/mol.53.1.123

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  43 in total

1.  Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses.

Authors:  T C Bellamy; J Wood; D A Goodwin; J Garthwaite
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 2.  Isoforms of NO-sensitive guanylyl cyclase.

Authors:  Michael Russwurm; Doris Koesling
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

Review 3.  Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.

Authors:  George F Lasker; Jason H Maley; Edward A Pankey; Philip J Kadowitz
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

4.  Properties of NO-activated guanylyl cyclases expressed in cells.

Authors:  Barry J Gibb; Victoria Wykes; John Garthwaite
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

5.  Aspartate 102 in the heme domain of soluble guanylyl cyclase has a key role in NO activation.

Authors:  Padmamalini Baskaran; Erin J Heckler; Focco van den Akker; Annie Beuve
Journal:  Biochemistry       Date:  2011-05-02       Impact factor: 3.162

6.  Probing the local electronic and geometric properties of the heme iron center in a H-NOX domain.

Authors:  Zhou Dai; Elizabeth M Boon
Journal:  J Inorg Biochem       Date:  2011-03-13       Impact factor: 4.155

Review 7.  Novel therapies for cyclic GMP control of vascular smooth muscle growth.

Authors:  David A Tulis
Journal:  Am J Ther       Date:  2008 Nov-Dec       Impact factor: 2.688

8.  YC-1 binding to the β subunit of soluble guanylyl cyclase overcomes allosteric inhibition by the α subunit.

Authors:  Rahul Purohit; Bradley G Fritz; Juliana The; Aaron Issaian; Andrzej Weichsel; Cynthia L David; Eric Campbell; Andrew C Hausrath; Leida Rassouli-Taylor; Elsa D Garcin; Matthew J Gage; William R Montfort
Journal:  Biochemistry       Date:  2013-12-30       Impact factor: 3.162

9.  The nitric oxide-cGMP signaling pathway differentially regulates presynaptic structural plasticity in cone and rod cells.

Authors:  Nan Zhang; Annie Beuve; Ellen Townes-Anderson
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

10.  Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans.

Authors:  Takashi Nakai; Nicholas R Perl; Timothy C Barden; Andrew Carvalho; Angelika Fretzen; Peter Germano; G-Yoon J Im; Hong Jin; Charles Kim; Thomas W-H Lee; Kimberly Long; Joel Moore; Jason M Rohde; Renee Sarno; Chrissie Segal; Erik O Solberg; Jenny Tobin; Daniel P Zimmer; Mark G Currie
Journal:  ACS Med Chem Lett       Date:  2016-02-24       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.